Evidence map›Paper›PMID 40000722›Full record

ArticleScientific reports2025

Discovery and characterization of a novel telomerase alternative splicing isoform that protects lung cancer cells from chemotherapy induced cell death.

Jeongjin J Kim, Alexander Ahn, Jeffrey Y Ying, Andrew T Ludlow

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jeongjin J KimSchool of Kinesiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Alexander AhnSchool of Kinesiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Jeffrey Y YingSchool of Kinesiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Andrew T LudlowSchool of Kinesiology, University of Michigan, Ann Arbor, MI, 48109, USA. atludlow@umich.edu.

Funding

Manipulating hTERT splicing in lung cancer cells.R00CA197672 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUDLOW, ANDREW TODD · 2017 to 2019
$738k
NCI NIH HHS 5R00CA197672-04NCI NIH HHS R00 CA197672
6 · The paper itself

Abstract

All cancer cells must adopt a telomere maintenance mechanism to achieve replicative immortality. Most human cancer cells utilize the enzyme telomerase to maintain telomeres. Alternative splicing of TERT regulates the amount and function of telomerase, however many alternative splicing isoforms of TERT have unknown functions. Single molecule long read RNA/cDNA sequencing of TERT revealed 45 TERT mRNA variants including 13 known and 32 novel variants. Among the variants, TERT Delta 2-4, which lacks exons 2-4 but retains the original open reading frame, was selected for further study. Induced pluripotent stem cells and cancer cells express higher levels of TERT Delta 2-4 compared to primary human bronchial epithelial cells. Overexpression of TERT Delta 2-4 enhanced clonogenicity and resistance to cisplatin-induced cell death. Knockdown of endogenous TERT Delta 2-4 in Calu-6 cells reduced clonogenicity and resistance to cisplatin. Our results suggest that TERT Delta 2-4 enhances cancer cells' resistance to cell death. RNA sequencing following knockdown of Delta 2-4 TERT indicates that translation is downregulated and that mitochondrial related proteins are upregulated compared to controls. Overall, our data indicate that TERT produces many isoforms that influence the function of TERT and the abundance and activity of telomerase.

Indexed as

Alternative SplicingAntineoplastic AgentsLung NeoplasmsTelomeraseCell DeathCell Line, TumorCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansIsoenzymesProtein IsoformsAntineoplastic AgentsCisplatinIsoenzymesProtein IsoformsTelomeraseTERT protein, humanAlternative RNA splicingLung cancerTelomeraseTERT

Identifiers

PMID40000722
PMCPMC11861669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.